Alnylam Pharmaceuticals (ALNY) Revenue Growth (3y) (2012 - 2026)
Alnylam Pharmaceuticals (ALNY) Revenue Growth (3y) (2012 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 50.07% |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 7.94% |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | 4.47% |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | 79.44% |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | - |
| 10 | Alnylam Pharmaceuticals | 37.29 Bn | 34.28 Bn | 959.66 Mn | 54.05% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 54.05% |
| Dec 31, 2025 | 48.49% |
| Sep 30, 2025 | 67.81% |
| Jun 30, 2025 | 50.98% |
| Mar 31, 2025 | 40.71% |
| Dec 31, 2024 | 31.89% |
| Sep 30, 2024 | 38.72% |
| Jun 30, 2024 | 44.09% |
| Mar 31, 2024 | 40.68% |
| Dec 31, 2023 | 39.05% |
| Sep 30, 2023 | 81.34% |
| Jun 30, 2023 | 45.28% |
| Mar 31, 2023 | 47.51% |
| Dec 31, 2022 | 67.20% |
| Sep 30, 2022 | 55.67% |
| Jun 30, 2022 | 71.32% |
| Mar 31, 2022 | 85.72% |
| Dec 31, 2021 | 130.78% |
| Sep 30, 2021 | 349.28% |
| Jun 30, 2021 | 94.65% |